Medical devices, healthcare technology and the business of care
PMA approval · P200036

eCoin Peripheral Neurostimulator

BOSTON SCIENTIFIC CORPORATION · Decision date Mar 1, 2022

MEDTECHLEDGER EXPLANATIONP200036

What did the FDA approve?

The FDA record for P200036 shows an original PMA approval, dated 2022-03-01, for the eCoin Peripheral Neurostimulator from Boston Scientific Corporation. The product code is QPT, categorized as an implantable electrical tibial stimulator for urinary incontinence, with gastroenterology and urology listed as specialties. No supplement type or supplement reason appears in the record, so the scope described is the original approval rather than a later change to an existing PMA.

The supplied statement describes the device as intended to treat urgency urinary incontinence in patients who are intolerant to, or have an inadequate response to, other more conservative treatments, or who have undergone a successful trial of percutaneous tibial nerve stimulation. That wording is the statement's reported purpose; the record contains no independent safety or clinical effectiveness data and no details on the trial referenced. Specifics such as device design, stimulation parameters and post-approval requirements are absent.

FDA approval order statement

Approval of the eCoin Peripheral Neurostimulator. The device is intended to be used to treat urgency urinary incontinence in patients intolerant to or having an inadequate response to other more conservative treatments or who have undergone a successful trial of percutaneous tibial nerve stimulation.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Mar 1, 2022

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200036
Regulatory pathway
Premarket approval application
Product code
QPT
Decision code
APPR
Decision date
Mar 1, 2022
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.

Product code
QPT
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200036 received

    Application receipt date recorded by FDA.

  2. P200036 · FDA decision

    APPR

  3. P200036/S009 · Related supplement

    eCoin Tibial Nerve Stimulator System

  4. P200036/S010 · Related supplement

    eCoin Peripheral Neurostimulator

  5. P200036/S011 · Related supplement

    eCoin Peripheral Neurostimulator

  6. P200036/S012 · Related supplement

    eCoin Peripheral Neurostimulator

Timeline entries are records held by MedtechLedger for P200036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200036

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 2, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 3, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 20, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementSep 9, 2026FDA

Explore the linked device profile

Other records with product code QPT

Product / regulatory recordCompanyPathwayDecision dateSource
AltavivaP240011/S016
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
AltavivaP240011/S015
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
AltavivaP240011/S010
Medtronic NeuromodulationPMA supplementJul 13, 2026FDA
AltavivaP240011/S014
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
AltavivaP240011/S013
Medtronic NeuromodulationPMA supplementMay 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
100 Boston Scientific Way, Marlborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records